Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a phase 3 trial: Assessment of Pruritus

被引：0
|
作者：
Blauvelt, Andrew [1 ]
Draelos, Zoe [2 ]
Gooderham, Melinda [3 ,4 ]
Lain, Edward [5 ]
Moore, Angela [6 ,7 ]
Papp, Kim [8 ,9 ]
Zirwas, Matthew [10 ,11 ]
Krupa, David [12 ]
Burnett, Patrick [12 ]
Berk, David [12 ]
Chu, David [12 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Dermatol Consulting Serv, San Diego, CA USA
[3] Probity Med Res, SKiN Ctr Dermatol, Waterloo, ON, Canada
[4] Queens Univ, Kingston, ON, Canada
[5] Sanova Dermatol, Baton Rouge, LA USA
[6] Arlington Res Ctr, Arlington, TX USA
[7] Baylor Univ Med Ctr, Dallas, TX USA
[8] Probity Med Res, Waterloo, ON, Canada
[9] K Papp Clin Res, Waterloo, ON, Canada
[10] Probity Med Res, Cent States, Waterloo, ON, Canada
[11] Ohio Univ, Athens, OH 45701 USA
[12] Arcutis Biotherapeut Inc, Westlake Village, CA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
42835
引用
收藏
页码：AB156 / AB156
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a phase 3 trial: assessment of pruritus
    Blauvelt, Andrew
    Draelos, Zoe D.
    Gooderham, Melinda
    Lain, Edward
    Moore, Angela Y.
    Papp, Kim A.
    Zirwas, Matthew
    Krupa, David
    Burnett, Patrick
    Berk, David R.
    Chu, David H.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [2] EFFICACY AND SAFETY OF ROFLUMILAST FOAM 0.3% IN PATIENTS WITH SEBORRHEIC DERMATITIS IN A PHASE 3 TRIAL: ASSESSMENT OF PRURITUS
    Blauvelt, A.
    Draelos, Z. D.
    Gooderham, M.
    Lain, E.
    Moore, A. Y.
    Papp, K. A.
    Zirwas, M.
    Krupa, D.
    Burnett, P.
    Berk, D. R.
    Chu, D. H.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S59 - S59
  • [3] Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a randomized, double-blind, vehicle-controlled phase 2 study
    Zirwas, Matthew
    Draelos, Zoe D.
    DuBois, Janet
    Kircik, Leon
    Moore, Angela
    Gold, Linda Stein
    Higham, Robert C.
    Navale, Lynn
    Burnett, Patrick
    Berk, David R.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB47 - AB47
  • [4] Efficacy and safety results of a randomized, double-blind, vehicle-controlled phase 2 study of roflumilast foam 0.3% in patients with seborrheic dermatitis
    Zirwas, M.
    [J]. EXPERIMENTAL DERMATOLOGY, 2021, 30 : 13 - 13
  • [5] Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial
    Blauvelt, Andrew
    Draelos, Zoe D.
    Gold, Linda Stein
    Alonso-Llamazares, Javier
    Bhatia, Neal
    DuBois, Janet
    Forman, Seth B.
    Gooderham, Melinda
    Green, Lawrence
    Guenthner, Scott T.
    Hebert, Adelaide A.
    Lain, Edward
    Moore, Angela Y.
    Papp, Kim A.
    Zirwas, Matthew
    Kato, Saori
    Snyder, Scott
    Krupa, David
    Burnett, Patrick
    Berk, David R.
    Chu, David H.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (05) : 986 - 993
  • [6] Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial
    Zirwas, Matthew J.
    Draelos, Zoe D.
    DuBois, Janet
    Kircik, Leon H.
    Moore, Angela Y.
    Gold, Linda Stein
    Alonso-Llamazares, Javier
    Bukhalo, Michael
    Bruce, Suzanne
    Eads, Kimmie
    Green, Lawrence J.
    Guenthner, Scott T.
    Ferris, Laura K.
    Forman, Seth B.
    Kempers, Steven E.
    Lain, Edward
    Lynde, Charles W.
    Pariser, David M.
    Toth, Darryl P.
    Yamauchi, Paul S.
    Higham, Robert C.
    Krupa, David
    Burnett, Patrick
    Berk, David R.
    [J]. JAMA DERMATOLOGY, 2023, 159 (06) : 613 - 620
  • [7] Roflumilast foam 0.3% treatment of seborrheic dermatitis is effective and safe and improves patient quality of life: Results from a phase 2 study
    Draelos, Zoe D.
    Forman, Seth B.
    Green, Lawrence J.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB105 - AB105
  • [8] Anti-fungal effects on Malassezia species in an open-label, phase 1, maximal use study of roflumilast foam 0.3% in patients with seborrheic dermatitis
    Zirwas, M.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2024, 144 (08) : S96 - S96
  • [9] IMPACT OF ROFLUMILAST FOAM 0.3% ON PATIENTREPORTED QUALITY OF LIFE IN SEBORRHEIC DERMATITIS: AN ANALYSIS OF STRATUM DATA FOR PATIENTS UNRESPONSIVE OR INTOLERANT TO TOPICAL CORTICOSTEROIDS
    Chu, D. H.
    Stephenson, B.
    Lee, J.
    Bannister, B.
    Hickey, C.
    Westley, T.
    Zirwas, M.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S488 - S488
  • [10] Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis
    Bunick, Christopher G.
    Bhatia, Neal
    Del Rosso, James
    Draelos, Zoe D.
    Eichenfield, Lawrence F.
    Kircik, Leon H.
    Lebwohl, Mark G.
    Gooderham, Melinda
    Green, Lawrence J.
    Hebert, Adelaide A.
    Vender, Ronald B.
    Zirwas, Matthew
    Simpson, Eric L.
    Gold, Linda Stein
    Seal, Melissa
    Snyder, Scott
    Osborne, David W.
    Burnett, Patrick
    Higham, Robert C.
    Chu, David H.
    Berk, David R.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
12345